Artificial intelligence and machine learning have moved from experimental tools to practical components of drug discovery, clinical development, manufacturing, and medical device innovation. In the US life sciences sector, adoption has accelerated through the mid-2020s. Understanding this shift helps clarify how work is changing and what it means for people working in these fields.
This overview looks at the trajectory of AI use across pharma, biotech, and medtech, then examines its effects on human roles. The picture that emerges is one of augmentation more than wholesale replacement, with new hybrid skills rising in importance.
The Past: Early Experiments and Limited Reach
Before the early 2020s, AI applications in life sciences were mostly confined to research settings. Computational chemists and bioinformaticians used machine learning for target identification, virtual screening, and basic predictive modeling. These tools helped generate hypotheses but rarely drove major decisions on their own.
In medical devices, early AI focused on image analysis in radiology and pathology. The FDA had authorized only a small number of AI/ML enabled devices by the late 2010s. Most systems required significant human oversight, and regulatory frameworks were still forming. Data quality, limited computing power, and siloed information slowed broader progress. Many organizations ran isolated pilots that never scaled.
The Present: Widespread Adoption with Clear Boundaries
By 2026, AI has become embedded across multiple functions. In drug discovery, machine learning models support target prioritization, molecular design, and protein structure prediction. Some companies report measurable reductions in early discovery timelines. Clinical operations use AI for patient matching, site selection, protocol optimization, and real-world evidence analysis. Manufacturing teams apply predictive models for process control, yield improvement, and quality monitoring.
Medical devices show particularly strong progress. The FDA has authorized more than 1,000 AI/ML enabled devices, with radiology still the largest category but cardiology, diagnostics, and software as a medical device growing quickly. Digital twins and process optimization tools are gaining ground in manufacturing environments.
Despite this activity, most AI systems operate with humans firmly in the loop. Regulatory requirements, accountability for patient safety, and the need to interpret complex biological data keep people central to decision making. Many organizations still struggle to move pilots into full production because of data quality issues, validation challenges, and the need for specialized talent that understands both the science and the technology.
Investment continues to rise, and agentic AI systems that can plan and execute multi step workflows are beginning to appear in controlled settings. Yet fully autonomous AI designed drugs or devices remain rare. Human judgment, experimental validation, and regulatory sign off continue to define the critical path.
The Future: Deeper Integration and Redesigned Workflows
Looking ahead, AI is expected to expand further into operational and decision support roles. Agentic systems may handle larger portions of literature review, experiment design, data cleaning, and routine documentation. Manufacturing facilities could incorporate more autonomous process adjustments within validated boundaries. Clinical trial design and monitoring may rely more heavily on continuous AI analysis of incoming data.
Some organizations envision laboratories and production environments designed around AI agents, with human experts focusing on oversight, exception handling, and strategic direction. In medical devices, adaptive algorithms that update with new data under controlled frameworks are likely to become more common.
Progress will depend on stronger data foundations, clearer regulatory guidance, and the ability to demonstrate consistent value. Companies that treat AI as infrastructure rather than a series of experiments are expected to pull ahead. At the same time, high-stakes decisions involving patient safety, novel mechanisms, or complex regulatory submissions will almost certainly retain meaningful human involvement for the foreseeable future.
How AI Affects Human Roles
AI is changing the nature of work more than eliminating large categories of jobs in the near term. Routine and repetitive tasks face the greatest pressure. Manual data cleaning, standard literature screening, basic image triage, and certain templated reporting activities are increasingly automated. In manufacturing, some lower skilled repetitive production tasks may decline as automation and process AI expand.
Most scientific, clinical, and regulatory roles are being augmented rather than replaced. Discovery scientists use AI to generate and prioritize ideas more quickly, then apply domain expertise to interpret results and design confirmatory experiments. Clinical teams rely on AI for operational efficiency while retaining responsibility for protocol decisions, patient safety, and data integrity. Regulatory professionals use AI tools for document drafting and consistency checks but remain accountable for strategy and agency interactions.
New and expanded roles are emerging at the intersection of science and technology. Demand is strong for AI and machine learning scientists who understand biology or clinical data, computational biologists, bioinformaticians, and clinical data scientists. Hybrid positions that combine domain knowledge with AI fluency, such as regulatory professionals who can evaluate model validation or quality specialists who oversee AI driven process controls, are particularly sought after. Roles focused on AI governance, model validation in regulated environments, MLOps for life sciences systems, and data product ownership are also growing.
The most valuable professionals are often those who can work effectively with AI outputs: questioning results, recognizing limitations, integrating findings with experimental evidence, and maintaining accountability. Organizations report ongoing difficulty finding people with this combination of skills.
Looking Ahead for Talent and Organizations
The introduction of AI is reshaping skill requirements across pharma, biotech, and medical devices. Purely manual roles face compression, while positions that blend scientific judgment with technical fluency are expanding. Humans remain essential for interpretation, ethical oversight, regulatory accountability, and the creative problem solving that drives genuine innovation.
Companies that invest in both technology and the people who can use it effectively are better positioned to capture value. Professionals who develop comfort with AI tools while deepening their domain expertise will find more opportunities. The shift is less about replacement and more about redistribution of effort toward higher value work.
AI will continue to influence how medicines and devices are discovered, developed, manufactured, and monitored. The organizations and individuals who adapt thoughtfully, keeping human expertise at the center of critical decisions, are likely to navigate the transition most successfully.
About GForce Life Sciences
GForce has been at the leading edge of AI adoption with life sciences companies of all shapes and sizes. If you have a project where you would like to discuss GForce’s capabilities in these areas, please contact us.